- Home
- SHPH vs ATXI Comparison
SHPH vs ATXI Comparison
Compare SHPH & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- ATXI
- Stock Information
- Founded
- SHPH 2012
- ATXI 2015
- Country
- SHPH United States
- ATXI United States
- Employees
- SHPH N/A
- ATXI N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- SHPH Health Care
- ATXI Health Care
- Exchange
- SHPH Nasdaq
- ATXI Nasdaq
- Market Cap
- SHPH 2.7M
- ATXI 3.0M
- IPO Year
- SHPH 2022
- ATXI 2017
- Fundamental
- Price
- SHPH $0.64
- ATXI $1.84
- Analyst Decision
- SHPH
- ATXI
- Analyst Count
- SHPH 0
- ATXI 0
- Target Price
- SHPH N/A
- ATXI N/A
- AVG Volume (30 Days)
- SHPH 74.0K
- ATXI 26.2K
- Earning Date
- SHPH 11-13-2024
- ATXI 11-14-2024
- Dividend Yield
- SHPH N/A
- ATXI N/A
- EPS Growth
- SHPH N/A
- ATXI N/A
- EPS
- SHPH N/A
- ATXI N/A
- Revenue
- SHPH N/A
- ATXI N/A
- Revenue This Year
- SHPH N/A
- ATXI N/A
- Revenue Next Year
- SHPH N/A
- ATXI N/A
- P/E Ratio
- SHPH N/A
- ATXI N/A
- Revenue Growth
- SHPH N/A
- ATXI N/A
- 52 Week Low
- SHPH $0.61
- ATXI $1.60
- 52 Week High
- SHPH $4.94
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- SHPH 27.09
- ATXI 44.82
- Support Level
- SHPH $0.61
- ATXI $1.80
- Resistance Level
- SHPH $0.79
- ATXI $1.88
- Average True Range (ATR)
- SHPH 0.06
- ATXI 0.13
- MACD
- SHPH 0.00
- ATXI -0.01
- Stochastic Oscillator
- SHPH 12.15
- ATXI 40.70
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.